Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Utilization of Point-of-Care Ultrasound in Routine Patient Care Among Internal Medicine Resident Physicians in the United States.

American journal of medicine open·2026

Same author

Treatment-Emergent Bictegravir Resistance in a Treatment-Naive Individual With HIV Infection: A Case Report.

Cureus·2026

Same author

Evaluation of a Resident Wellness Curriculum: A Cross-Sectional Survey in an Internal Medicine Residency Program.

Cureus·2026

Same author

Chronic Stress, Diabetes, and Cardiovascular Disease: Epidemiologic Evidence, Pathogenetic Insights, and Therapeutic Strategies.

Cureus·2026

Same author

Letter to the editor: impact of beta blockers on long-term mortality in Takotsubo syndrome: a real-world analysis of the TriNetX global collaborative network database.

European heart journal. Acute cardiovascular care·2026

Same author

A Case of Extensive Thromboembolism as a First Presentation of a Pheochromocytoma: Pathophysiologic Insights and Strategic Surgical Intervention.

Cureus·2025

Search research articles

Related Experiment Video

Updated: May 26, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Telmisartan and cardioprotection.

Philippe R Akhrass¹, Samy I McFarlane

¹State University of New York, Downstate Medical Center, Brooklyn, NY 11203, USA.

Vascular Health and Risk Management

|December 6, 2011

Summary

Telmisartan, an angiotensin receptor blocker (ARB), shows promise in reducing cardiovascular risk. Clinical trials like ONTARGET and TRANSCEND evaluated its cardioprotective effects in high-risk patients.

Area of Science:

Cardiology
Pharmacology
Internal Medicine

Background:

The renin-angiotensin-aldosterone system (RAAS) is implicated in atherosclerosis and cardiovascular disease (CVD) pathogenesis.
RAAS blockade, particularly with angiotensin converting enzyme (ACE) inhibitors, is a recognized cardioprotective strategy.
Angiotensin receptor blockers (ARBs) effectively lower blood pressure, but their role in CVD risk reduction is under investigation.

Purpose of the Study:

To highlight the cardioprotective role of telmisartan, an ARB.
To review the findings of the ONTARGET and TRANSCEND randomized controlled trials regarding telmisartan's efficacy.

Main Methods:

Review of two major randomized controlled trials: ONTARGET and TRANSCEND.
Evaluation of telmisartan's effects on cardiovascular endpoints in high-risk patient populations.

Keywords:

ONTARGET TRANSCEND cardioprotection telmisartan

Related Experiment Videos

Last Updated: May 26, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Comparison of telmisartan alone versus in combination with ramipril (ONTARGET) and telmisartan in ACE inhibitor-intolerant patients (TRANSCEND).

Main Results:

Telmisartan demonstrated a promising role in reducing cardiovascular risk in high-risk individuals.
ONTARGET trial results provided insights into telmisartan's efficacy and safety profile.
TRANSCEND study assessed telmisartan's benefits in patients intolerant to ACE inhibitors.

Conclusions:

Telmisartan emerges as a significant therapeutic option for cardiovascular risk reduction.
The findings support the use of telmisartan in managing high-risk cardiovascular patients.
Further research may elucidate the full potential of telmisartan in cardioprotection.